CPH · STRAP.CO
Strategic Partners A/S
DKK 635.00-DKK 15.00 (-2.31%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
Loading market information…
OTC · SCPS · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Scopus BioPharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Scopus BioPharma Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$0.22. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Scopus BioPharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Scopus BioPharma Inc. is a biopharmaceutical company in the clinical development phase, dedicated to pioneering innovative treatments for serious diseases. Its core development programs are concentrated on immuno-oncology gene therapies designed to combat various forms of cancer. The company's offerings include the Duet Platform, which incorporates CpG signal transducer and activator of transcription 3 (STAT3) inhibitors. Another significant product is MRI-1867, a cleverly engineered, orally administered, dual-action hybrid small molecule. MRI-1867 functions as an inverse agonist of the endocannabinoid system's cannabinoid receptor 1 (CB1) and additionally acts as an inhibitor of inducible nitric oxide synthase (iNOS). To advance its key development efforts and other programs, Scopus BioPharma has established strategic collaborations with prominent organizations such as the City of Hope, the National Institutes of Health Program, and The Hebrew University of Jerusalem. Established in 2017, the company was originally named Project18 Inc. before officially rebranding to Scopus BioPharma Inc. in December of that year. Its corporate headquarters are located in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 635.00-DKK 15.00 (-2.31%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
$0.03+$0.03 (+26,900.0%)
Vaxxinity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.5% below the high.
$0.00+$0.00 (0.0%)
PaxMedica, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 96.5% below the high.
$0.00$0.00 (0.0%)
Regenicin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
$0.00$0.00 (0.0%)
VioQuest Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (0.0%)
Q BioMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
RenovaCare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
Medite Cancer Diagnostics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
